Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease (Q24202510)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

chronic obstructive pulmonary disease

14 May 2020

main subject

placebo

0 references

0 references

author

Phillippa Poole

2

0 references

Phillippa Poole

2

object named as

Phillippa Poole

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

author name string

Luis Javier Nannini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

Stephen J Milan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

Rebecca Holmes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

Rebecca Normansell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

language of work or name

English

0 references

publication date

10 November 2013

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

page(s)

CD003794

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Adherence to inhaled therapy, mortality and hospital admission in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Seretide for obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Use of dry powder inhalers in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Inhaled corticosteroids in COPD: quantifying risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Immunologic aspects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Lung function impairment, COPD hospitalisations and subsequent mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Bronchodilator reversibility in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

12 December 2020

[Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]

1 reference

12 December 2020

Premature discontinuation of patients: a potential bias in COPD clinical trials

1 reference

12 December 2020

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

1 reference

12 December 2020

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial

1 reference

12 December 2020

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

1 reference

12 December 2020

Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives

1 reference

12 December 2020

Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD

1 reference

12 December 2020

St. George's Respiratory Questionnaire: MCID

1 reference

12 December 2020

Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study

1 reference

12 December 2020

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

12 December 2020

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

12 December 2020

Fixed‐dose combination inhalers compared to long‐acting bronchodilators for COPD: a network meta‐analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB4

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD003794.PUB4

2 references

Consolidated OpenCitations Corpus – April 2017

2275721

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

2275721

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6485527&resulttype=core&format=json

14 May 2020

2 references

Consolidated OpenCitations Corpus – April 2017

2275721